LB Pharmaceuticals Inc (LBRX)
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing therapies for schizophrenia, bipolar depression, and other neuropsychiatric disorders. Its lead candidate, LB-102, is an oral small-molecule therapy that is being evaluated in a Phase 3 clinical trial for acute schizophrenia. The program has also completed a Phase 2 study in bipolar I depression and has been assessed as an adjunctive treatment for major depressive disorder, while a long-acting injectable formulation remains in the pre-clinical stage. Incorporated in 2015, the company is headquartered in New York, New York, and its common stock trades on the NASDAQ under the ticker LBRX.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-LBRX
|
$22.13
|
-31.0% Downside
|
Overvalued
|
$45.13
|
40.7% Upside
|
Undervalued
|
Great
|
—
|
—
|
—
|
0.0%
|
September 2, 2026
|
-23.6x
|
2.4x
|
—
|
886.1 M
|
557.8 M
|
0.4%
|
63.1%
|
36.2
|
—
|
129.5%
|
